PSC
GILD icon

Piper Sandler & Co’s Gilead Sciences GILD Stock Holding History

Piper Sandler & Co’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,800
Closed -$165K – 11
2016
Q1 		$165K Buy
+1,800
New +$162K 0.36% 7

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Piper Sandler & Co's GILD Position: Q2 2016 in Review

Piper Sandler & Co sold out of Gilead Sciences (GILD) in Q2 2016, closing a stake of 1,800 shares — an estimated $165K sold.

Piper Sandler & Co first reported a position in GILD in Q1 2016 and held it in 1 quarter. The position peaked at $165K in Q1 2016. 1,596 funds tracked by Wall St. Rank hold GILD as of Q2 2016.

  • Piper Sandler & Co reported no remaining Gilead Sciences position as of Q2 2016 after selling out during the quarter.
  • Piper Sandler & Co sold 1,800 Gilead Sciences shares in Q2 2016, an estimated $165K.
  • Piper Sandler & Co first reported a position in Gilead Sciences in Q1 2016 and held it in 1 quarter.
  • Piper Sandler & Co's Gilead Sciences position peaked at $165K in Q1 2016.
  • 1,596 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2016.

Based on Piper Sandler & Co's 13F filing for Q2 2016, filed 15 Aug 2016.